Effect of Growth Hormone Replacement Therapy on Plasma Brain Natriuretic Peptide Concentration, Cardiac Morphology and Function in Adults with Growth Hormone Deficiency

Abstract

Objective: The impact of growth hormone (GH) replacement on plasma brain natriuretic peptide (BNP) in association with cardiac morphology and function in adults with growth hormone deficiency (GHD) was evaluated.

Subjects and Methods: Fifty nine adult patients with GHD (29 men, age 19–59 years) received a starting dose of 0.1–0.2 mg/day recombinant GH, which was subsequently adjusted to the 50th percentile of normal serum insulin-like growth factor (IGF-1) over a 6 month period. Plasma BNP and IGF-I levels before, 3 and 6 months after treatment were determined, as were the echocardiographic data, such as ejection fraction (EF), left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic diameter (LVEDD), interventricular septal thickness (IVST), posterior wall thickness (PWT), left ventricular mass (LVM), E/A wave and deceleration time (DT).

Results: Mean plasma BNP levels (53.1±8 pg/ml) and echocardiographic parameters were within the normal range at baseline, although men had higher LVM, IVST, PWT, LVEDV and LVEDD, respectively. A significant decrease in plasma BNP was observed after 6 months (27±5.6 pg/ml, P<0.05). No significant changes in echocardiographic parameters were observed except for a mild tendency to increase in LVM, and a borderline decrease in DT (181±8.1 vs. 155±9 ms, P<0.01).

Conclusions: Six months GH replacement therapy induced a significant decrease in plasma BNP levels despite the majority of patients having plasma BNP within the normal range at baseline. A borderline decrease in diastolic deceleration time was observed, the clinical significance of which is unclear.

Key words

Brain natriuretic peptide (BNP) - Echocardiography - Deceleration time - Growth hormone deficiency - Growth hormone replacement

References

• 1 Abs R, Rasmusen UF, Mattsson AF. et al . Determinants of cardiovascular risk in 2589 hypopituitary growth hormone deficient adults – a KIMS database analysis.  Eur J Endocrinol. 2006;  155 79-90
• 2 Amato G, Mazziotti G, Di Somma C. et al . Recombinant growth hormone therapy in growth hormone deficient adults: A long-Term Controlled Study on Daily Versus Thrice Weekly Injection.  J Clin Endocrinol Metab. 2000;  85 3720-3725
• 3 Andreassen M, Faber J, Vestergaard H. et al . N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances.  Clin Endocrinol. 2007;  66 619-625
• 4 Attanasio AF, Lamberts SW, Matranga AMC. et al . Adult growth hormone (GH) deficient patients demonstrate heterogeneity between Childhood onset and Adult onset before and During Human growth hormone treatment. Adult growth hormone deficiency study group.  J Clin Endocrinol Metab. 1997;  82 82-88
• 5 Baum HBA, Katznelson L, Sherman JC. et al . Effects of physiological growth hormone therapy on condition and quality of life in patients with adult onset GH deficiency.  J Clin Endocrinol Metab. 1998;  83 3184-3189
• 6 Begtsson BA, Johansson G, Shalet SM. et al . Treatment of growth hormone deficiency in adults.  J Clin Endocrinol Metab. 2000;  85 933-942
• 7 Burger AG, Monson JP, Colao AM. et al . Cardiovascular risk in patients with growth hormone deficiency effects of growth hormone substitution.  Endocr Prac. 2006;  12 682-689
• 8 Ceyhun C, Unal S, Yenisey C. et al . The role of N terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction:correlation with echocardiographic indexes in hypertensive patients.  Int J Card Imaging. 2007;  24 253-259
• 9 Cho G, Jeong I, Kim S. et al . Effect of growth hormone on cardiac contractility in patients with adult onset growth hormone deficiency.  Am J Cardiol. 2007;  100 1035-1039
• 10 Colao A, Di Somma C, Cuoccolo A. et al . Improved cardiovascular risk factors and cardiac performance after 12 months of GH replacement in young adult patients with growth hormone deficiency.  J Clin Endocrinol Metab. 2001;  86 1874-1881
• 11 Colao A, Vilale G, PivonelloR. et al . The heart: an end-organ of growth hormone action.  Eur J Endocrinol. 2004;  151 ((Suppl 1)) 93-101
• 12 Colao A, Di Somma C, Cuoccolo A. et al . Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology and performance and atherosclerosis? Results of a two-years open, prospective study in young adult men and women with severe GH deficiency.  J Clin Endocrinol Metab. 2005;  90 5146-5155
• 13 Colao A, Di Somma C, Rota F. et al . Short term effects of growth hormone treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency.  J Clin Endocrinol Metab. 2005;  90 2056-2062
• 14 Fischer M, Baessler A, Hense HW. et al . Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic – based survey of a population sample.  Eur Heart J. 2003;  24 320-325
• 15 Follin C, Thilén U, Ahrén B. et al . Improvement in cardiac systole function and reduced prevalence of metabolic syndrome after two years of growth hormone treatment in growth hormone deficient adult survivors of childhhod-onset acute lymphoblastic leukemia.  J Clin Endocrinol Metab. 2006;  91 1872-1875
• 16 Gotherstrom G, Bengtsson BA, Bosaeus I. et al . A 10-year, prospective study of the metabolic effects of growth hormone replacement in dults.  J Clin Endocrinol Metab. 2007;  92 1442-1445
• 17 Gutiérrez LP, Koltowska-Häggström M, Mattson AF. et al . Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database).  Pharmacoepidemiol Drug Saf. 2008;  17 90-102
• 18 Johansson G, Sverrisdotir YB, Ellegard L. et al . Growth hormone increases extracellular volume by stimulating Sodium reabsorption in the distal nephron and preventing pressure natriuresis.  J Clin Endocrinol Metab. 2002;  87 1743-1749
• 19 Lanes R, Gunczler P, Lopez E. et al . Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone deficient adolescents.  J Clin Endocrinol Metab. 2001;  86 1061-1065
• 20 Longobardi S, Cuocolo A, Merola B. et al . Left ventricular function in young adults with childhood and adult onset growth hormone deficiency.  Clin Endocrinol. 1998;  48 137-143
• 21 Merola B, Cittadini A, Colao A. et al . Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency.  J Clin Endocrinol Metab. 1993;  77 1658-1661
• 22 Minczykowski A, Gryczynska M, Ziemnicka K. et al . The influence of growth hormone therapy on ultrasound myocardial tissue characterisation in patients with childhood onset growth hormone deficiency.  Int J Cardiol. 2005;  101 257-263
• 23 Nakao S, Goda A, Yuba M. et al . Characterization of left ventricular filling abnormalities and its relation to elevated plasma BNP level in acute to chronic diastolic heart failure.  Circ J. 2007;  71 1412-1417
• 24 Valcavi R, Gaddi O, Zini M. et al . Cardiac preformance and mass in adults with hypopituitarism: effects of one year of GH treatment.  J Clin Endocrinol Metab. 1995;  80 659-666
• 25 Wallaschofski H, Saller B, Spilcke-Liss E. et al . Effects of growth hormone treatment on B type natriuretic peptide as a marker of heart failure in adults with growth hormone deficiency.  Horm Metab Res. 2006;  38 656-661

Correspondence